Unión Europea -
español -
EMA (European Medicines Agency)
jakavi
novartis europharm limited - ruxolitinib (como fosfato) - myeloproliferative disorders; polycythemia vera; graft vs host disease - agentes antineoplásicos - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. la policitemia vera (pv)jakavi está indicado para el tratamiento de pacientes adultos con policitemia vera que son resistentes o intolerantes a la hidroxiurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
Venezuela -
español -
Instituto Nacional de Higiene
jakavi 10 mg comprimidos
novartis de venezuela, s.a. - ruxolitinib - comprimidos - 10 mg
Venezuela -
español -
Instituto Nacional de Higiene
jakavi 15 mg comprimidos
novartis de venezuela, s.a. - ruxolitinib - comprimidos - 15 mg
Venezuela -
español -
Instituto Nacional de Higiene
jakavi 20 mg comprimidos.
novartis de venezuela, s.a. - ruxolitinib - comprimidos - 20 mg
Venezuela -
español -
Instituto Nacional de Higiene
jakavi 5 mg comprimidos
novartis de venezuela, s.a. - ruxolitinib - comprimidos - 5 mg